Details of the Drug
General Information of Drug (ID: DMOT1LQ)
| Drug Name |
2-Hydrazino-3-methyl-4(3H)-quinazolinone
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
2-hydrazino-3-methylquinazolin-4(3H)-one; 61507-80-0; 2-Hydrazino-3-methyl-3H-quinazolin-4-one; 2-Hydrazino-3-methyl-4(3H)-quinazolinone; NSC657432; CHEMBL503552; 2-hydrazinyl-3-methylquinazolin-4(3H)-one; 2-hydrazinyl-3-methylquinazolin-4-one; BAS 00718750; 4(3H)-Quinazolinone,2-hydrazinyl-3-methyl-; 2-hydrazinyl-3-methyl-3,4-dihydroquinazolin-4-one; 2-hydrazino-3-methyl-3-hydroquinazolin-4-one; AC1Q6DRE; AC1L8CIY; AC1Q3XQM; 2-Hydrazino-3-methyl-3 H -quinazolin-4-one; Oprea1_318278; Oprea1_401830; MLS000713036; CTK5B3345
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 190.2 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


